Sponsor scenarios

Australia is attractive because the sponsor has identified two experienced specialist centres and wants a credible early clinical dataset before committing to a larger global program.

Clintrail can act as the Australian sponsor for the defined study, with Australian sponsor obligations documented separately from the US company's product ownership, clinical strategy, funding, and investor reporting responsibilities.

The company avoids the time, cost, and governance burden of setting up an Australian subsidiary solely to hold the sponsor role for a first local study.

The company does not want to alter its global operating model or incorporate in Australia for a limited Australian arm of the clinical trial.

Clintrail can hold the Australian sponsor role while the European team retains control of the IVD development plan, protocol, statistical and data strategy, specimen handling model, central or reference laboratory arrangements, and global vendor oversight.

The Australian study can be structured around a local sponsor without forcing a permanent local corporate footprint before the program has proven its commercial value.

The company has financing in place and needs first patient in on a defined timeline, but it does not have an Australian entity and does not want local company formation to slow activation.

Clintrail can act as the Australian sponsor for the Phase I study, manage TGA-facing sponsor responsibilities in Australia, and put a clear responsibility split in place for safety reporting, startup, and study conduct while the Asian sponsor retains global development control.

The sponsor can move into Australian startup with a defined local sponsor model, without delaying site activation while setting up a subsidiary purely to hold the Australian sponsor role.

Australia is attractive because the program team wants additional recruitment capacity, high-quality data, and a jurisdiction that can fit into an existing multinational operating model.

Clintrail can act as the Australian sponsor for the Australian arm while the European company keeps global clinical trial leadership, product ownership, vendor oversight, safety database control, and overall program accountability outside the Australian sponsor role.

The company can add Australia to a mature Phase III program without creating a local subsidiary solely for the sponsor role, while documenting how Australian sponsor responsibilities, safety reporting, site contracts, and governance will work inside the global trial structure.